Additionally, acute myeloid leukemia with NPM1 mutations (without FLT3–ITD) or in-frame CEBPA mutations in the basic leucine zipper region is now categorized as favorable-risk due to its heightened sensitivity to chemotherapy [1,40]. Here, NPM1 is linked to acute myeloid leukemia.